2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2413

Inflammation Regulating microRNAs, Mir-146b, Mir-155 and Mir-192-5p Are Altered in Plasma and Synovial Fluid of Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 2414

Microrna Associated with Active Systemic Juvenile Idiopathic Arthritis Regulate CD163 Expression in Polarized Macrophages through Two Distinct Mechanisms
Abstract Number: 2415

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (secHLH)
Abstract Number: 2416

Antibodies to Citrullinated Peptides in Patients with Juvenile Idiopathic Arthritis and Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype
Abstract Number: 2417

High Dimensional Interrogation of the T Cell Immunome in Polyarticular Juvenile Idiopathic Arthritis Patients
Abstract Number: 2418

Rnaseq Reveals Treatment-Associated Gene Expression Dynamics in Juvenile Idiopathic Arthritis CD4+ T Cells
Abstract Number: 2419

Single-Cell Analysis of CD163 mRNA and Protein Expression By Primeflow™ in Polarized Monocyte and Macrophage Populations
Abstract Number: 2420

Investigating Genome-Wide Inbreeding Coefficients and Age of Diagnosis in a Multi-Ethnic Population of Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 2421

Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2422

Cyclic Amp, Erk5, and Transdifferentiation of Cardiac Fibroblasts in the Pathogenesis of Autoimmune Congenital Heart Block
Abstract Number: 2423

Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Abstract Number: 2424

Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Abstract Number: 2425

The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Abstract Number: 2426

Transcriptomic Analysis of Immune Subsets in Juvenile Dermatomyositis before and after Treatment Identifies Novel Pathways Involved in Pathogenesis
Abstract Number: 2427

Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].